From ADHD to off-label uses, we detail how to dose atomoxetine, how pharmacogenomic testing affects it, and how it compares with stimulants and the other antidepressant for ADHD, viloxazine (Qelbree).

Now that guanfacine ER (Intuniv) and clonidine ER (Kapvay) have gone generic, we review the 40-years of research that earned them FDA approval in ADHD. Along the way we’ll consider their off-label use in anxiety, addiction, insomnia, and self-harm. Plus: When to use the ER, the instant release, or the oft-forgotten transdermal patch.

Quitting smoking remains extremely difficult. This multicenter randomized controlled trial evaluates the efficacy of using e-cigarettes compared to nicotine replacement among adults (average age 41) seeking help to quit smoking.

Internet and computer game addictions represent difficult-to-define and difficult-to-treat conditions that are increasing in prevalence. To provide some guidance on treatment options, investigators tested short-term cognitive behavioral therapy in a randomized, controlled trial.

Polypharmacy is often practiced in schizophrenia, but you have to look hard to find any evidence that it helps. These two large-scale studies lend some empiric support to the practice, but also give us insights into how it could go wrong.

Lithium is underutilized in geriatric depression, but this study suggests it may have unique benefits there.